Clinical trials: IPMN, open to volunteers
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, IPMN, Pancreatic
Pancreatic Cancer Initial Detection Via Liquid Biopsy
The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient…
- Conditions
- Pancreatic Cancer, IPMN, Pancreatic, Individuals at Risk, Chronic Pancreatitis
- Trial name
- PANCAID (NCT06283576)
- Testing
- Liquid biopsy
- Where
- Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Intraductal Papillary Mucinous Neoplasm
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
- Trial name
- NCT05433935
- Testing
- Observation
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
IPMN, Pancreatic Cancer
Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms
BACKGROUND: Patients with trivial branch duct intraductal papillary mucinous neoplasm (BD IPMN) which remain s stable over 5 years reportedly do not have an increased risk of developing pancreatic cancer (PC) compared to the…
- Trial name
- TRIVIAL (NCT07056972)
- Testing
- Discontinuation of surveillance
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Padova
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico